HRAS Mutations and Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Head and Neck Squamous Cell Carcinoma Cells

BACKGROUND: This was to identify mechanisms of innate resistance to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. Specifically, we analyzed the role of HRAS mutations in erlotinib resistance. M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hah, J. Hun, Zhao, Mei, Pickering, Curtis R., Frederick, Mitchell J., Andrews, Genevieve A., Jasser, Samar A., Fooshee, David R., Milas, Zvonimir L., Galer, Chad, Sano, Daisuke, William, William N., Kim, Edward, Heymach, John, Byers, Lauren A., Papadimitrakopoulou, Vali, Myers, Jeffrey N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010580/
https://ncbi.nlm.nih.gov/pubmed/24123531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23499
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados